Saia Francesco, de Feyter Pim, Serruys Patrick W, Lemos Pedro A, Arampatzis Chourmouzios A, Hendrickx Guy R, Delarche Nicholas, Goedhart Dick, Lesaffre Emmanuel, Branzi Angelo
Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands.
Am J Cardiol. 2004 Jan 1;93(1):92-5. doi: 10.1016/j.amjcard.2003.08.076.
We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30% compared with placebo (95% confidence interval -49 to -3.4, p = 0.03).
在来适可干预预防研究（LIPS）中，我们评估了长期服用氟伐他汀对847例平均胆固醇水平的患者（氟伐他汀组[n = 417]或安慰剂组[n = 430]）不良动脉粥样硬化性心脏事件（心脏死亡、心肌梗死和血运重建，不包括因最初6个月内再狭窄而进行的重复干预）的影响。在4年的随访期内，与安慰剂相比，氟伐他汀显著降低了总胆固醇和低密度脂蛋白胆固醇水平，并使首次发生不良动脉粥样硬化性心脏事件的风险降低了30%（95%置信区间为-49至-3.4，p = 0.03）。
